Monobactams

Finberg, Robert W.; Guharoy, Roy

doi:10.1007/978-1-4614-1068-3_6

Search citation statements

Order By: Relevance

Paper Sections

Select...

Monobactams1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2014

Publication Types

Select...

Book1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

(1 citation statement)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…2). The sulfonic acid group is thought to activate the b-lactam ring assisting the acylation of transpeptidases (Finberg and Guharoy 2012). Aztreonam is currently the only clinically approved monobactam.…”

Section: Monobactamsmentioning

confidence: 99%

The Mechanisms of Resistance to β-Lactam Antibiotics

King

Sobhanifar

Strynadka

2014

Handbook of Antimicrobial Resistance

View full text Add to dashboard Cite

Bacterial diseases have had an enormous impact on human health and continue to be a major focus in modern medicine. The most widespread class of human antibacterials is the b-lactams that target the transpeptidase enzymes, which are responsible for cross-linking the peptidoglycan cell wall. There are over 34 FDA-approved b-lactams which together constitute $50 % of all antibiotic prescriptions worldwide (Tahlan K and Jensen SE, J Antibiot (Tokyo) 66:401-410, 2013). However, bacteria have gained resistance mechanisms to overcome all major classes of b-lactam antibiotics to date. In this chapter, we will address the major mechanisms of bacterial resistance to the b-lactams and highlight some of the recent advances in circumventing this resistance.

show abstract

Section: Monobactamsmentioning

confidence: 99%